Good MorningThe major indices were mostly flat on Tuesday as earnings season kicks into high gear. The onslaught of reports was met with little fanfare although it is still early in the season. On balance, more companies than average are beating their consensus earnings estimates although by a smaller margin than expected. If this trend persists through the end of the reporting season the market may find itself stuck in a trading range until a new catalyst emerges.
Reports that may move the market on Wednesday include Microsoft, Starbucks, AMD and Apple. Apple is slated to report after the bell and could be a turning point for the market. The company’s earnings estimates have been moving steadily higher since early summer and may be hard to beat. Anything less than a stunning report may be too little to keep share prices trading at all-time high levels.
Featured: Wall Street’s quietly buying these 3 AI infrastructure plays (Ad) 
|
Markets | | U.S. major automobile manufacturer Ford Motor Company (NYSE: F) stock has recently rallied on the electric vehicle (EV) momentum that has finally flowed from first movers like Tesla (NASDAQ:TSLA) into the traditional U.S. automakers lead by General Motors (NYSE: GM). Shares up over 25% year-to-date ... Read the Full Story |
|
From Our Partners | | BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid.
The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | | Get the name, the ticker, and exactly how to buy it |
|
Markets | | Regional Banks Poised For Growth In 2021
The financial sector (NYSEARCA:XLF) is poised for a major rebound in 2021 and not just the big banks. The smaller regional and community banks may not come with the same exposures but are still well-situated to benefit from the coming economic boom. When I s... Read the Full Story |
|
Medical | |
In what many analysts are calling a frothy market, Johnson & Johnson (NYSE:JNJ) must be wondering what gives? The iconic big pharma company is being held to a mighty high standard. It’s true that Johnson & Johnson is supposed to be a steady Eddie stock without a lot of volatility. Bu... Read the Full Story |
|
From Our Partners | | See the Signals Most Traders Miss
We monitor subtle shifts in order flow, volume patterns, and early trend behavior.
Stock News Trends highlights moves long before they hit mainstream screens. | | Join Free — Start Tracking Early Market Data |
|
Basic Materials | | H.B. Fuller Is A Great Way To Ride Out The Reopening
If you are looking for a single stock to ride out the post-pandemic boom then H.B. Fuller Company (NYSE:FUL) may be it. The company manufactures specialty chemicals worldwide which doesn’t sound all that exciting I know but wait until you ... Read the Full Story |
|
Technology | | Semiconductor chip maker Taiwan Semiconductor Manufacturing Company (NYSE: TSM) stock has been on a near parabolic ascent as the fabless trend continues to gain momentum. Taiwan Semi is the world’s largest chip maker where some of the largest technology companies outsource the manufacturing of... Read the Full Story |
|
From Our Partners | | With OpenAI and Anthropic moving closer to the IPO spotlight, AI excitement could spill into several public-market sectors this summer - and most investors may chase the obvious names too late.
A free report identifies 7 stocks positioned around themes that could matter most this summer: AI infrastructure, energy demand, travel, entertainment, home improvement, and more. Built for a market where leadership may rotate quickly. | | Download 7 Best Stocks to Own in Summer 2026 for free |
|
Consumer Discretionary | | Flexsteel Beats Q2 Consensus In Transformational Quarter
Flexsteel Industries, Inc (NASDAQ:FLXS) has been on our radar for some time now. The company emerged as a pandemic-play and turnaround story early in the year and ensuring rebound has only surpassed our expectations. The company is one of Nor... Read the Full Story |
|
Consumer Discretionary | | Even with tech stocks hitting fresh all time highs again this week, Wall Street isn’t slowing down with its long recommendations. On Monday, Goldman Sachs was out with an upgrade to shares of rivals Electronic Arts (NASDAQ: EA), Take-Two (NASDAQ: TTWO) and Activision Blizzard (NASDAQ: ATVI).
... Read the Full Story |
|
Retail/Wholesale | | McDonald’s (NYSE: MCD) is set to release its Q4 earnings on Friday; like a lot of restaurants, the fast-food giant was happy to see the calendar turn to 2021.
That said, McDonald’s shares performed well in 2020. After bottoming in March with the rest of the market, shares nearly doubled... Read the Full Story |
|
Retail/Wholesale | |
For those who thought the era of the mall-facing retailer was gone for good, brought low by online shopping and ultimately dispatched by COVID-19 restrictions, the news may not be so dire as previously expected. We can base that on recent reports that give American Eagle Outfitters (NYSE:AEO) a br... Read the Full Story |
|
Consumer Staples | | Kimberly-Clark Is A Stock You Can Own Forever
We have highlighted Kimberly-Clark (NYSE:KMB) as a stock you can own forever on more than one occasion. The company offers value, a safe dividend, and growth in a well-established bluechip name. The latest earnings release not only confirms that thesis ... Read the Full Story |
|
The Early Bird Stock Of The Day Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. | | View Today's Stock Pick |
|
